PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
UnitedHealthcareMedicaid · Prior Auth · Medical Benefit Drug Policy · NM · Genetics, Pediatrics, Endocrinology +1 moreMedium impact

Genglycos ™ (Pariglasgene Brecaparvovec-Opnr)

Effective date
Dec 1, 2026
Identified
Nov 7, 2026

Summary

UnitedHealthcare Community Plan of New Mexico added Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy for glycogen storage disease type Ia, to its Medicaid medical benefit drug policy as a new policy effective 2026-12-01. Coverage is limited to patients aged 8 or older with confirmed diagnosis (G6PC bi-allelic variants or absent G6Pase activity on liver biopsy), current cornstarch therapy, no detectable AAV8 antibodies, no prior gene therapy, specialist prescribing, no planned inpatient admission solely for administration, FDA-labeled dosing, and authorization for one lifetime treatment lasting no more than 45 days from approval.

Get alerts when payers change rules like this one

We check UnitedHealthcare and other payers every day and email you when a change matches your specialty and state.

Get UnitedHealthcare alertsPolicy Monitoring is free. No card required.

What to do

Action · 3 steps
01By 2026-12-01: Billing team should set up prior authorization intake for Genglycos for New Mexico Community Plan Medicaid members, confirm the request packet requires the diagnosis confirmation records, cornstarch therapy documentation, AAV8 antibody status, prior gene therapy history, and specialist involvement, and track the 45-day authorization window from approval in the prior auth tracker.
02Providers and front desk staff should be told that planned inpatient admissions requested solely for administering Genglycos fall outside the listed criteria, so scheduling and facility orders should be reviewed before the service is booked.
03Claims for Genglycos should be entered with the authorization number and documentation attached so they go out with the required supporting records.

Original notice

Genglycos ™ (Pariglasgene Brecaparvovec-Opnr)
uhcprovider.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account